INDIVIOR PHARMACEUTICALS INC (INDV) Fundamental Analysis & Valuation

NASDAQ:INDV • US45579U1097

30.87 USD
-1.11 (-3.47%)
At close: Mar 3, 2026
30.87 USD
0 (0%)
After Hours: 3/3/2026, 8:19:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This INDV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

INDV gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While INDV belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. INDV is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

7

1. INDV Profitability Analysis

1.1 Basic Checks

  • In the past year INDV was profitable.
  • INDV had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: INDV reported negative net income in multiple years.
  • In multiple years INDV reported negative operating cash flow during the last 5 years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • The Return On Assets of INDV (8.62%) is better than 89.64% of its industry peers.
  • With an excellent Return On Invested Capital value of 50.62%, INDV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for INDV is significantly above the industry average of 12.91%.
  • The 3 year average ROIC (43.06%) for INDV is below the current ROIC(50.62%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROIC 50.62%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • Looking at the Profit Margin, with a value of 10.34%, INDV belongs to the top of the industry, outperforming 84.46% of the companies in the same industry.
  • INDV's Profit Margin has declined in the last couple of years.
  • The Operating Margin of INDV (24.49%) is better than 92.23% of its industry peers.
  • INDV's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of INDV (85.51%) is better than 88.60% of its industry peers.
  • INDV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. INDV Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), INDV is creating value.
  • There is no outstanding debt for INDV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • INDV has an Altman-Z score of 2.61. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.61, INDV is in the better half of the industry, outperforming 67.88% of the companies in the same industry.
  • The Debt to FCF ratio of INDV is 2.68, which is a good value as it means it would take INDV, 2.68 years of fcf income to pay off all of its debts.
  • INDV has a Debt to FCF ratio of 2.68. This is amongst the best in the industry. INDV outperforms 93.26% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Altman-Z 2.61
ROIC/WACC5.37
WACC9.43%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INDV's Current ratio of 0.96 is on the low side compared to the rest of the industry. INDV is outperformed by 84.97% of its industry peers.
  • INDV has a Quick Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INDV has a Quick ratio of 0.79. This is amonst the worse of the industry: INDV underperforms 80.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.79
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. INDV Growth Analysis

3.1 Past

  • INDV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 459.09%, which is quite impressive.
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%

3.2 Future

  • INDV is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.07% yearly.
  • INDV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.79% yearly.
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue Next Year-2.8%
Revenue Next 2Y1.11%
Revenue Next 3Y1.73%
Revenue Next 5Y0.79%

3.3 Evolution

INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. INDV Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 12.55, the valuation of INDV can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 88.60% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.83, INDV is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 10.02, the valuation of INDV can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 88.60% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.95, INDV is valued rather cheaply.
Industry RankSector Rank
PE 12.55
Fwd PE 10.02
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 84.97% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, INDV is valued cheaply inside the industry as 82.38% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 32.17
EV/EBITDA 12.31
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • INDV has a very decent profitability rating, which may justify a higher PE ratio.
  • INDV's earnings are expected to grow with 13.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.5
PEG (5Y)N/A
EPS Next 2Y17.02%
EPS Next 3Y13.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INDV Dividend Analysis

5.1 Amount

  • INDV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INDV Fundamentals: All Metrics, Ratios and Statistics

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (3/3/2026, 8:19:42 PM)

After market: 30.87 0 (0%)

30.87

-1.11 (-3.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)04-22
Inst Owners92.33%
Inst Owner Change-70.46%
Ins Owners3.78%
Ins Owner Change31.01%
Market Cap3.86B
Revenue(TTM)N/A
Net Income(TTM)122.00M
Analysts84.62
Price Target46.48 (50.57%)
Short Float %9.21%
Short Ratio5.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.33%
PT rev (3m)24.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.31%
EPS NY rev (1m)0%
EPS NY rev (3m)79.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.81%
Valuation
Industry RankSector Rank
PE 12.55
Fwd PE 10.02
P/S 3.27
P/FCF 32.17
P/OCF 21.45
P/B N/A
P/tB N/A
EV/EBITDA 12.31
EPS(TTM)2.46
EY7.97%
EPS(NY)3.08
Fwd EY9.98%
FCF(TTM)0.96
FCFY3.11%
OCF(TTM)1.44
OCFY4.66%
SpS9.43
BVpS-1.66
TBVpS-1.67
PEG (NY)0.5
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROCE 64.08%
ROIC 50.62%
ROICexc 3805.17%
ROICexgc 5707.75%
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
FCFM 10.17%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Debt/EBITDA 0.97
Cap/Depr 230.77%
Cap/Sales 5.08%
Interest Coverage 250
Cash Conversion 57.14%
Profit Quality 98.36%
Current Ratio 0.96
Quick Ratio 0.79
Altman-Z 2.61
F-Score8
WACC9.43%
ROIC/WACC5.37
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year-2.8%
Revenue Next 2Y1.11%
Revenue Next 3Y1.73%
Revenue Next 5Y0.79%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1050.98%
EBIT Next 3Y148.27%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%

INDIVIOR PHARMACEUTICALS INC / INDV FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 5 / 10 to INDV.


What is the valuation status of INDIVIOR PHARMACEUTICALS INC (INDV) stock?

ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


What is the profitability of INDV stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


How financially healthy is INDIVIOR PHARMACEUTICALS INC?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


Is the dividend of INDIVIOR PHARMACEUTICALS INC sustainable?

The dividend rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 0 / 10 and the dividend payout ratio is 0%.